Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 12/20 | 0.56 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | PAK3 | O75914 | 2/20 | 0.38 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.38 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20680268 | 0.84 | CD38 (0.73) | CD38PRMT5WDR77ACLY | |
| SCHEMBL16099139 | 0.77 | NPY5R (0.52) | CD38KDM4E | |
| SCHEMBL20183820 | 0.74 | KDM4E (0.45) | KDM4E | |
| SCHEMBL21476669 | 0.73 | KDM4E (0.47) | KDM4E | |
| SCHEMBL28395908 | 0.72 | CD38 (1.00) | CD38 | |
| SCHEMBL28395907 | 0.72 | CD38 (1.00) | CD38 | |
| SCHEMBL23117527 | 0.71 | CD38 (0.66) | CD38 | |
| SCHEMBL23117525 | 0.71 | CD38 (0.66) | CD38 | |
| SCHEMBL23117454 | 0.71 | CD38 (1.00) | CD38 | |
| SCHEMBL23117453 | 0.71 | CD38 (1.00) | CD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087290-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2021-03-25 | — | — | US | disclosed |
| EP-3658586-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2020-06-03 | — | — | EP | disclosed |
| WO-2019020643-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2019-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087290-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | CD38, TRPC1, TRPC4 | CD38 1/4885PAK1 2614/4885PRMT5 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.